Click Therapeutics vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
$50M Series D from Boehringer Ingelheim in Apr 2026. Develops prescription digital therapeutics for depression, schizophrenia, and other conditions.
About
Click Therapeutics develops FDA-regulated prescription digital therapeutics (PDT) for conditions including depression, schizophrenia, migraine, and smoking cessation. The company partners with pharma — including Boehringer Ingelheim, Otsuka, and Sanofi — to co-develop and commercialize PDTs alongside traditional pharmacologic treatments.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
Key Details
Also Compare
Click Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.